Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy

Table 3

Ongoing clinical trials in neoadjuvant setting in PDAC.

Treatment	Setting	Trial identification number	Phase	Design
Gemcitabine	BRPC	NCT01458717	II/III	Upfront surgery versus neoadjuvant gemcitabine-based chemoradiation therapy
Gemcitabine/Oxaliplatin	Resectable PC	NCT01314027	III	Adjuvant gemcitabine versus neoadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine
Gemcitabine + RT	Resectable PC	NCT01900327	II	Chemoradiation with gemcitabine + RT followed by surgery and adjuvant gemcitabine versus upfront surgery plus adjuvant gemcitabine
Gemcitabine + RT	BRPC and LAPC	NCT01739439	I	Hypofractionated chemoradiation with gemcitabine plus radiosurgical boost
Gemcitabine + CP-870,893 + RT	Resectable PC	NCT01456585	I	Gemcitabine plus CD40 agonist antibody CP-870,893 followed by addition of CP-870,893 versus adjuvant chemoradiation
Gemcitabine + capecitabine	Resectable PC	NCT01360593	II	Gemcitabine + capecitabine + RT
Gemcitabine + erlotinib	Resectable PC	NCT00733746	II	Gemcitabine + erlotinib before and after surgery
Nab-paclitaxel + gemcitabine	Resectable PC	NCT02047513	III	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer
Nab-paclitaxel + gemcitabine + LDE225	BRPC	NCT01431794	II	Gemcitabine and nab-paclitaxel with LDE225 (oral hedgehog inhibitor)
FOLFIRINOX	Resectable PC	NCT01661088	II	FOLFIRINOX followed by combined modality treatment with gemcitabine during and following RT
FOLFIRINOX	Resectable PC	NCT01677988	II	FOLFIRINOX and chemoradiation followed by surgery
FOLFIRINOX	BRPC	NCT01821612	II	FOLFIRINOX and chemoradiation followed by surgery and adjuvant gemcitabine
FOLFIRINOX	Resectable PC	NCT01446458	I	RT and neoadjuvant FOLFIRINOX
CAPOXIRI	Resectable PC, BRPC, and LAPC	NCT00087022	II	Neoadjuvant capecitabine, oxaliplatin, and irinotecan (CAPOXIRI)
Capecitabine + RT	BRPC	NCT00763516	II	Neoadjuvant proton beam radiation therapy and concomitant capecitabine
capecitabine and hydroxychloroquine + RT	Resectable PC	NCT01494155	II	Neoadjuvant accelerated short course RT with proton beam capecitabine and hydroxychloroquine
capecitabine, cisplatin, epirubicin, and gemcitabine	Resectable PC	NCT01150630	II/III	Peri- or postoperative chemotherapy with capecitabine, cisplatin, epirubicin, and gemcitabine
GTX + RT	BRPC	NCT01065870	II/III	Gemcitabine, capecitabine, and docetaxel (GTX) versus GTX + RT
GTX + RT	BRPC	NCT01754623	II	RT in combination with GTX
Gem, 5-FU Oregovomab, Nelfinavir + RT	LAPC	NCT01959672	II	Gemcitabine and 5-FU with and without immunotherapy (Oregovomab) followed by RT and Nelfinavir
Tegafur, cetuximab + RT	LAPC	NCT01050426	II	Tegafur, leucovorin, and concomitant RT with or without cetuximab
IMRT + IORT	Resectable PC	NCT01372735	II	IMRT in combination with surgery and intraoperative radiation therapy (IORT) followed by adjuvant chemotherapy